IP Library Granted Patent US 12,344,860
Granted Patent B2
US 12,344,860 · App. 17/156,062 · Granted Jul 1, 2025

Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof

Inventors: Robert Lane Smith (Palo Alto, CA); Laurence J. B. Tarrant (Northhampton, MA); Akihiko Kusanagi (Brookline, MA); Hans P. I. Claesson (Wayland, MA)
Assignee: Ocugen, Inc.
C12N5/0068A61L27/24A61L27/3817A61L27/3843A61L27/56C12N5/0655A61F2/08A61F2002/30062A61F2/30756A61F2/3872A61F2210/0004A61F2310/00365A61L2400/18A61L2430/06A61L2430/10C12N2533/54C12N2535/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,860
App. No.
17/156,062
Granted
Jul 1, 2025
Kind
B2
Abstract

A cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof. The matrix suitable for preparation of cellular or acellular implants for growth and de novo formation of an articular hyaline-like cartilage. A gel-matrix composite system comprising collagen-based matrix having a narrowly defined porosity capable of inducing hyaline-like cartilage production from chondrocytes in vivo and in vitro.

Claims (15)

1. A collagen-based cell-support matrix having narrowly defined and uniformly vertically and non-randomly organized porosity and pore density wherein said matrix is prepared from a collagen-based biocompatible material, wherein said porosity is determined by pore size and wherein said pore size is substantially homogeneous in diameter.

2. The matrix of claim 1 wherein said biocompatible material comprises:

(i) a collagen selected from the group consisting of Type I collagen, Type II collagen, and Type IV collagen, and

(ii) optionally gelatin, agarose, hyaluronin, cell-contracted collagen containing proteoglycan, glycosaminoglycan, glycoprotein, fibronectin, laminin, bioactive peptide growth factors, cytokine, elastin, fibrin, synthetic polymeric fiber made of A poly-acid polylactic, polyglycolic, polyamino acid, polycaprolactone, polypeptide gel, a copolymer thereof, a precursor thereof and combination thereof, wherein said precursor is selected from the group consisting of alpha 1 (Type I) peptide, alpha 2 (Type I) peptide, 2 (alpha 1, Type I) peptide, 1 (alpha 2, Type I) peptide, 3 (alpha 1, Type II) and a combination thereof.

3. The matrix of claim 2 wherein said biocompatible material is Type I collagen.

4. The matrix of claim 3 wherein said pore size is set to be at least 95% homogeneous within a range of about 200±100 microns.

5. The matrix of claim 4 wherein said matrix is suitable as an acellular or a cellular implant for treatment and repair of articular cartilage injuries or damage.

6. The matrix of claim 4 wherein said matrix is suitable for an acellular or a cellular implant for treatment of connective tissue injuries.

7. The matrix of claim 4 wherein said matrix is suitable for in vitro production of a hyaline or hyaline-like cartilage, tendon, ligament or meniscus.

8. The matrix of claim 3 wherein said pore size is set to be at least 98% homogeneous within a range of about 200±100 microns.

9. A collagen-based support matrix having narrowly defined and uniformly vertically and non-randomly organized porosity and pore density wherein said matrix is prepared from a Type I collagen, wherein said porosity is determined by the pore size of about 200±100 microns and wherein said pore size is about 95% homogeneous.

10. The matrix of claim 9 seeded with a suspension of chondrocytes in a gel solution.

11. The matrix of claim 10 wherein said gel is collagen, a sol-gel or hydrogel.

12. The matrix of claim 11 wherein said sol-gel has a transition temperature from sol to gel about 37° C.

13. The matrix of claim 9 wherein said chondrocytes are seeded in cell density of from about 25,000 to about 300,000 cells per 25 microliters.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2022
From: SMITH, R. LANE; TARRANT, LAURENCE J.B.; KUSANAGI, AKIHIKO; CLAESSON, HANS P.I.
To: HISTOGENICS CORPORATION
Reel/Frame 060824/0213 →
CHANGE OF NAME Recorded Aug 16, 2022
From: HISTOGENICS CORPORATION
To: OCUGEN, INC.
Reel/Frame 061297/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2022
From: SMITH, ROBERT LANE; TARRANT, LAURENCE J.B.; KUSANAGI, AKIHIKO; CLAESSON, HANS P.I.
To: HISTOGENICS CORPORATION
Reel/Frame 060394/0166 →
CHANGE OF NAME Recorded Jul 3, 2022
From: HISTOGENICS CORPORATION
To: OCUGEN, INC.
Reel/Frame 060572/0633 →
Continuity (6)
Continuation 16706372 · Dec 6, 2019
Continuation 15641773 · Jul 5, 2017
Continuation 14577610 · Dec 19, 2014
Continuation 11523833 · Sep 19, 2006
Provisional Application 60718714 · Sep 19, 2005
Related Publication 20210246418A1 · Aug 12, 2021
References Cited (5)
US 8070827B2 · Shortkroff · 2011 [cited by examiner]
US 8106008B2 · Lynch · 2012 [cited by examiner]
WO WO2007057175A2 · 2007 [cited by examiner]
Guan J, Fujimoto KL, Sacks MS, Wagner WR “Preparation and Characterization of Highly Porous, Biodegradable Polyurethane Scaffolds for Soft Tissue Applications” Biomaterials. Jun. 2005 (ePub Dec. 8, 2004); 26(18): 3961-3… [cited by examiner]
Kozan NG, et al.“Aligned Collagen Sponges with Tunable Pore Size for Skeletal Muscle Tissue Regeneration” J. Funct. Biomater. Oct. 24, 2023, 14(11), 533; 18 pages; doi: 10.3390/jfb14110533. (Year: 2023). [cited by examiner]